Search the Newsreel

Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M

* Scienture Holdings, Inc. press release [https://seekingalpha.com/pr/20619685-scienture-reports-q2-2026-results-with-approximately-510-percent-sequential-revenue-growth] (SCNX [https://seekingalpha.com/symbol/SCNX]): Q2 Non-GAAP EPS of -$0.07. * Revenue of $0.34M. * Net loss for Q2 2026 narrowed 58% YoY to $2.82M from $6.72M in Q2 2025. * Gross profit was $0.34M with a gross margin of …

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and …

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences Corporation EW is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share. The question is whether that momentum warrants …

Scienture Holdings 2Q Loss/Shr 7c >SCNX

Scienture Holdings reported a second-quarter loss of 7 cents per share. Additionally, Unity Software reported its fourth-quarter financial results with revenue increasing 35% year-over-year to $609 million, exceeding estimates, despite reporting a quarterly loss of 66 cents per share. The article provides financial data …

Will Ciena's Rising Backlog Improve Revenue Visibility Into 2027?

Ciena Corporation is experiencing strong demand and a growing backlog, which is expected to provide increased revenue visibility into fiscal 2027. The company's backlog surged to $7.7 billion in Q2 fiscal 2026, with a significant portion anticipated to convert into revenue within the next …

Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss

Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …

TuHURA Biosciences, Inc. - Common Stock (HURA) Stock Price, News, Quote & History

This article provides a comprehensive overview of TuHURA Biosciences, Inc. (HURA) stock, including its current price, market data, and recent news. It highlights the company's focus on advancing biotechnology solutions, particularly in developing therapies and diagnostic tools. The news section features updates on their …

Armistice Capital (RKDA holder) discloses 9.99% beneficial stake in Arcadia Biosciences

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Arcadia Biosciences, Inc., totaling 267,392 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, exercising shared voting and dispositive power. …

Form 8K Skye Bioscience Inc For: 14 August By Investing.com

This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside

Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.

Evropi Societe Anonyme : Announcement 6059/2026

Die Thermo-Fisher-Aktie legt nach starken Quartalszahlen zu

GUFICBIO: Q1 FY27 saw strong profit growth and a major international expansion into the Philippines

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase …

TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization …

ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside

ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. …

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences reported a wider-than-expected Q2 2026 loss of $1.05 per share, surpassing the Zacks Consensus Estimate of a 97-cent loss. Despite increased R&D expenses for pipeline development, the company's cash position is expected to sustain operations into 2027. Kodiak is accelerating regulatory submissions …

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside

Analysts have cut the 12-month average price target for Caribou Biosciences, Inc. stock from $12 to $11.86, with individual forecasts ranging from $4 to $32 per share. Despite the slight reduction in the average target, this still implies a significant 636% potential upside based …

Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure

Alamar Biosciences (ALMR) stock surged 30.7% after its first post-IPO quarter, despite reporting a net loss of US$13.2m. The company achieved US$29.4m in revenue and a record 60% gross margin, driven by strong demand for consumables and instruments. While bulls highlight top-line growth and …

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line

Skye Bioscience is set to acquire Redx through a UK court-sanctioned scheme of arrangement, backed by a significant financing package. The deal includes a $67.9 million equity financing (potentially rising to $72.9 million), a $22.0 million equity line, and a $5.0 million warrant with …

Proficient Auto Logistics completes Hansen & Adkins acquisition

Proficient Auto Logistics (NASDAQ:PAL) has completed its acquisition of Hansen & Adkins, as announced in a press release. This acquisition positions the combined entity as the largest auto hauler in North America, expecting to transport over four million vehicles annually and handle approximately one-quarter …

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, forming a combined company named Fibrx Therapeutics, which will focus on developing novel small molecule medicines for fibrotic diseases. This merger is supported by approximately $125 million in financings, including a PIPE financing …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G/A for Artelo Biosciences (ARTL), reporting that they no longer beneficially own any common stock in the company. As of June 30, 2026, their ownership stake is 0 shares, representing 0.0% of the …

TMC Life Sciences nearly doubles profit in 4Q, proposes 0.58 sen dividend

TMC Life Sciences Berhad Posts Strong Earnings and Strengthens Balance Sheet in FY2026

Eurofins Scientific: Director/PDMR Shareholding

LUXEMBOURG, August 14, 2026--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse …

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences (RKDA) announced its second quarter and first half 2026 financial results, highlighting a significant reduction in cash used in operating activities and a strong cash balance. The company reported flat sales for Q2 2026 due to inventory and shipping issues, which have …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

HC Wainwright Has Bearish Estimate for DTIL Q3 Earnings

Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, has filed an amended Schedule 13G/A disclosing a beneficial ownership of 3.64% in MBX Biosciences (MBX). This group collectively holds 1,732,569 shares of common stock as of June 30, …

Following Acquisition, Proficient Expects to Move More Than 4M Vehicles a Year